Condition
Newly Diagnosed Acute Myeloid Leukemia (AML) clinical trials and research
Research outlook What's coming for Acute myeloid leukemia: the next 6 months to 5 yearsAs of November 12, 2026, Find a Trial lists 4 Newly Diagnosed Acute Myeloid Leukemia (AML) clinical trials that are recruiting, at sites in 3 countries (most in China (3), Australia (1), United Kingdom (1)). By phase: Phase 2 (1), Phase 1 (1), Phase 1/2 (1), Phase 3 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 3Countries
Newest Newly Diagnosed Acute Myeloid Leukemia (AML) clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Venetoclax with azacitidine, chidamide and CAG chemotherapy for fit older adults with AML | Phase 3 | Beijing, None Selected | Recruiting | Apr 7, 2026 |
| Alternating venetoclax+azacitidine and low-dose cladribine+homoharringtonine+cytarabine for unfit newly diagnosed AML | Phase 2 | Beijing, Beijing Municipality and 4 other locations | Recruiting | Sep 15, 2025 |
| Investigating APL-4098 with Azacitidine for treating relapsed or refractory AML and high-risk MDS | Phase 1 | Clayton, Victoria and 8 other locations | Recruiting | Apr 18, 2024 |
| Combining SKLB1028 with standard chemotherapy for newly diagnosed acute myeloid leukemia | Phase 1/2 | Chengdu | Recruiting | Jul 6, 2022 |
All recruiting trials (4)
-
Venetoclax with azacitidine, chidamide and CAG chemotherapy for fit older adults with AML
This will test whether adding venetoclax and chidamide to azacitidine plus CAG chemotherapy helps people aged 60-75 with newly diagnosed AML achieve remission more often than the standard 3+7 regimen.
-
Alternating venetoclax+azacitidine and low-dose cladribine+homoharringtonine+cytarabine for unfit newly diagnosed AML
This phase II trial tests whether alternating venetoclax + azacitidine with low-dose cladribine + homoharringtonine + cytarabine can help people aged ≥60 or otherwise unfit with newly diagnosed AML become MRD negative and achieve better disease control.
-
Investigating APL-4098 with Azacitidine for treating relapsed or refractory AML and high-risk MDS
This study is testing a new treatment called APL-4098, alone and with azacitidine, to see if it can help people with relapsed or hard-to-treat acute myeloid leukemia and high-risk myelodysplastic syndrome.
-
Combining SKLB1028 with standard chemotherapy for newly diagnosed acute myeloid leukemia
This study is testing if adding a new drug called SKLB1028 to standard chemotherapy helps people with newly diagnosed acute myeloid leukemia feel better and manage side effects.
Related topics
Quick answers
How many Newly Diagnosed Acute Myeloid Leukemia (AML) clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 3 countries. The most sites are in China (3 trials), Australia (1 trial), United Kingdom (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 1, Phase 1: 1, Phase 1/2: 1, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.